A、C、Y及W-135群脑膜炎球菌多糖蛋白结合疫苗
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
作者信息
Pace David, Pollard Andrew J
机构信息
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK.
出版信息
Arch Dis Child. 2007 Oct;92(10):909-15. doi: 10.1136/adc.2006.111500.
Abstract
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis.
摘要
C群脑膜炎球菌结合疫苗于1999年在英国首次推出，已在澳大利亚、加拿大和其他几个欧洲国家成功使用。已开发出包含多种脑膜炎球菌多糖的联合结合疫苗，以扩大对该疾病的保护范围。一种四价A、C、Y和W-135群脑膜炎球菌结合疫苗于2005年1月在美国获得许可，用于11至55岁的青少年和成人，随后于2006年5月在加拿大也被许可用于2至11岁的儿童。本文讨论了已开发的不同糖结合脑膜炎球菌疫苗及其用于控制由脑膜炎奈瑟菌A、C、Y和W-135群引起的疾病的潜力。
相似文献
1
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.A、C、Y及W-135群脑膜炎球菌多糖蛋白结合疫苗
Arch Dis Child. 2007 Oct;92(10):909-15. doi: 10.1136/adc.2006.111500.
2
Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.新型四价脑膜炎球菌 A、C、W-135 和 Y 荚膜多糖结合疫苗，为青少年和成年人提供更广泛的保护。
Future Microbiol. 2010 Nov;5(11):1629-40. doi: 10.2217/fmb.10.137.
3
Optimizing protection against meningococcal disease.优化针对脑膜炎球菌病的防护。
Clin Pediatr (Phila). 2010 Jun;49(6):586-97. doi: 10.1177/0009922809354327. Epub 2010 Jan 20.
4
Meningococcal disease: the advances and challenges of meningococcal disease prevention.脑膜炎球菌病：脑膜炎球菌病预防的进展与挑战
Hum Vaccin. 2011 Aug;7(8):828-37. doi: 10.4161/hv.7.8.16270. Epub 2011 Aug 1.
5
Meningococcal vaccine evolution.脑膜炎球菌疫苗的演变
J Prev Med Hyg. 2012 Sep;53(3):131-5.
6
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.用于从婴儿期起提供更广泛保护的四价ACYW-135脑膜炎球菌结合疫苗。
Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18.
7
Vaccines for the prevention of meningococcal disease in children.用于预防儿童脑膜炎球菌病的疫苗。
Semin Pediatr Infect Dis. 2002 Jul;13(3):182-9. doi: 10.1053/spid.2002.125861.
8
A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.一项评估幼儿使用不同配方的四价脑膜炎球菌（A、C、Y 和 W-135）结合破伤风蛋白疫苗的安全性和免疫原性的随机试验。
Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.
9
Challenges for development of meningococcal vaccines in infants and children.婴儿和儿童中流脑疫苗的研发挑战。
Expert Rev Vaccines. 2011 Mar;10(3):335-43. doi: 10.1586/erv.11.3.
10
[Group B meningococcal invasive infections: an unresolved public health problem].[B 群脑膜炎球菌侵袭性感染：一个尚未解决的公共卫生问题]
Rev Med Suisse. 2011 Feb 23;7(283):447-50.
引用本文的文献
1
Recent Progress in Developing Extracellular Vesicles as Nanovehicles to Deliver Carbohydrate-Based Therapeutics and Vaccines.开发细胞外囊泡作为纳米载体递送基于碳水化合物的治疗药物和疫苗的最新进展。
Vaccines (Basel). 2025 Mar 7;13(3):285. doi: 10.3390/vaccines13030285.
2
Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.≥56 岁成年人初次接种四价脑膜炎球菌结合疫苗（MenACYW-TT）5 年后的免疫持久性和加强免疫应答。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2426868. doi: 10.1080/21645515.2024.2426868. Epub 2024 Nov 18.
3
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.抗击侵袭性脑膜炎球菌病的十年：关于MenACWY-CRM结合疫苗临床及实际应用经验的叙述性综述
Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2.
4
Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale.在试点规模下开发和免疫巴西结合疫苗针对脑膜炎球菌 W 的研究
Glycoconj J. 2021 Oct;38(5):539-549. doi: 10.1007/s10719-021-10016-w. Epub 2021 Sep 13.
5
Carbohydrate based meningococcal vaccines: past and present overview.基于碳水化合物的脑膜炎球菌疫苗：过去和现在的概述。
Glycoconj J. 2021 Aug;38(4):401-409. doi: 10.1007/s10719-021-09990-y. Epub 2021 Apr 27.
6
Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates.疫苗抗原FHbp的变异信号肽会影响大多数脑膜炎球菌分离株中的加工过程，进而影响表面定位和抗体介导的杀伤作用。
Front Microbiol. 2019 Dec 19;10:2847. doi: 10.3389/fmicb.2019.02847. eCollection 2019.
7
Current trends in targeted therapy for drug-resistant infections.耐药感染的靶向治疗的当前趋势。
Appl Microbiol Biotechnol. 2019 Oct;103(20):8301-8314. doi: 10.1007/s00253-019-10028-5. Epub 2019 Aug 14.
8
9
Potential targets for next generation antimicrobial glycoconjugate vaccines.新一代抗菌糖缀合物疫苗的潜在靶标。
FEMS Microbiol Rev. 2018 May 1;42(3):388-423. doi: 10.1093/femsre/fuy011.
10
Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.建立疫苗研发的保护相关性：呼吸道合胞病毒疫苗领域的考量
Viral Immunol. 2018 Mar;31(2):195-203. doi: 10.1089/vim.2017.0147. Epub 2018 Jan 16.
本文引用的文献
1
Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.智利2至10岁健康儿童中A、C、Y、W-135群脑膜炎球菌多糖-白喉类毒素结合疫苗的安全性和免疫原性
Hum Vaccin. 2005 Nov-Dec;1(6):228-31. doi: 10.4161/hv.1.6.2301. Epub 2005 Nov 7.
2
Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006.最新消息：美国2005年10月至2006年2月期间，接种Menactra脑膜炎球菌结合疫苗的人群中出现格林-巴利综合征。
MMWR Morb Mortal Wkly Rep. 2006 Apr 7;55(13):364-6.
3
Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.青少年接种四价脑膜炎球菌结合疫苗3年后抗体的持久性
J Infect Dis. 2006 Mar 15;193(6):821-8. doi: 10.1086/500512. Epub 2006 Feb 8.
4
Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.既往接种过脑膜炎球菌C结合疫苗的儿童对脑膜炎球菌（A、C、Y和W135群）多糖-白喉类毒素结合疫苗的抗体反应。
Vaccine. 2006 Mar 24;24(14):2544-9. doi: 10.1016/j.vaccine.2005.12.018. Epub 2005 Dec 27.
5
Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.新型A、C、Y和W-135群脑膜炎球菌多糖-白喉类毒素结合疫苗（MCV-4）在健康青少年中的安全性、免疫原性及免疫记忆
Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13. doi: 10.1001/archpedi.159.10.907.
6
Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.一种研究性四价脑膜炎奈瑟菌-白喉类毒素结合疫苗在2岁儿童中的免疫原性。
Vaccine. 2005 Jul 29;23(34):4307-14. doi: 10.1016/j.vaccine.2005.03.031.
7
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).脑膜炎球菌病的预防与控制。免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2005 May 27;54(RR-7):1-21.
8
Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.C群脑膜炎球菌多糖疫苗的有效性：魁北克一项病例对照研究的结果
Clin Infect Dis. 2005 Apr 15;40(8):1116-22. doi: 10.1086/428729. Epub 2005 Mar 11.
9
Genetic analysis of meningococci carried by children and young adults.儿童和青年携带的脑膜炎球菌的基因分析。
J Infect Dis. 2005 Apr 15;191(8):1263-71. doi: 10.1086/428590. Epub 2005 Mar 15.
10
Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.使用一种研究性四价脑膜炎奈瑟菌-白喉类毒素结合疫苗免疫后两到三年，C群抗荚膜抗体的持续性。
Pediatr Infect Dis J. 2005 Feb;24(2):132-6. doi: 10.1097/01.inf.0000151035.64356.f8.
Zotero 插件